Episode 12: Among the topics: Primary prevention in the elderly – Acute and long-term treatment of pulmonary embolism

Mar 23, 2023

Ask episode

Chapters

Transcript

Episode notes

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies

Primary prevention in the elderly

Acute and long-term treatment of pulmonary embolism

Diagnostics Made Easy – “Getting things right” with the continuity equation for aortic stenosis

Host: Susanna Price

Guests: Jane Armitage and Stephan Rosenkranz

Want to watch that episode? Go to: https://esc365.escardio.org/event/923

Disclaimer

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Jane Armitage, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.

Victoria Delgado has declared to have potential conflicts of interest to report: speaker fees from Edwards Lifesciences, Medtronic, Novartis and Philips. Consulting fees from Edwards Lifesciences and Novo Nordisk.

Stephan Rosenkranz has declared to have potential conflicts of interest to report: speaker fees and consultation for Bayer, MSD, Boehringer-Ingelheim and Inari.

Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.